Liraglutide adverse event reports that FDA received

Name: Reaction terms in FDA adverse event reports that name Liraglutide
Creator: Reported Reactions
License: https://creativecommons.org/publicdomain/zero/1.0/

Name type: Generic name
Class: GLP-1 receptor agonist

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From February 2010 to June 2026, FDA received 1,446 adverse event reports that name Liraglutide. In these reports the drug is a suspect or interacting product.

In the same period, 1,519 further reports name it only as a concomitant medicine. The counts on this page do not include these reports.

FDA received 475 reports in the 12 months to June 2026 and 172 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

The number of people who use the product is not in the data. A count is not a rate. A count of reports is not a count of events or of patients, because one event can have more than one report.

There are many instances of duplicative reports and some reports do not contain all the necessary information.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Suspect product

FDA records each drug in a report as suspect, concomitant or interacting. This page counts the reports in which Liraglutide is suspect or interacting. FDA says:

Any number of the drugs may be marked as suspect if thought to be responsible for one or more of the reactions, but that information is not validated.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Data version

openFDA FAERS release of 1 Oct 2026. Reports received through 30 Jun 2026.

Since the last update

FDA says:

Many factors can influence whether or not an event will be reported, such as the time a product has been marketed and publicity about an event.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The information in these reports cannot be used to estimate the incidence (occurrence rates) of the events reported.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

No update is on record for this page. The record starts when FDA adds the reports of July to September 2026.

In April to June 2026, FDA received 194 reports that name Liraglutide.
In January to March 2026, FDA received 144.
In April to June 2025, FDA received 46.

April to June 2026 is the latest closed quarter in the data. A closed quarter is a quarter for which the FDA files have most of the reports.

All updates Feed of updates (RSS)

Reaction lookup

These are the reaction terms that the reports record, with the number of reports for each term. Type a term or a plain word to find its count.

What this list leaves out

The table lists the 181 reaction terms that 5 or more reports record. A term with fewer than 5 reports is not in the table.

The site keeps reaction terms for 1,416 of the 1,446 reports (97.9%).

The reports of the other years are not in the counts.

So a count in the table can be lower than the count of FDA.

Find a reaction term

The table shows the first 50 of 181 terms.

Reaction terms in the reports that name Liraglutide, most reports first
Reaction term (MedDRA) and plain meaning	Reports	Share of the 1,446 reports
Dyspnoeashortness of breath	179	12.4%
Anxiety	171	11.8%
Product dose omission issuea dose was missed	165	11.4%
Asthma	158	10.9%
Therapeutic product effect incomplete	157	10.9%
Obstructive airways disorder	155	10.7%
Condition aggravatedthe condition being treated got worse	153	10.6%
Hypothyroidismunderactive thyroid	153	10.6%
Wheezing	153	10.6%
Full blood count abnormal	148	10.2%
Loss of personal independence in daily activities	143	9.9%
Sleep disorder due to a general medical condition	136	9.4%
Neuritis	135	9.3%
Pulmonary alveolar haemorrhage	135	9.3%
Pulmonary fibrosis	135	9.3%
Haemoptysiscoughing up blood	134	9.3%
Lung disordera lung problem, type not specified	134	9.3%
Neurological symptom	134	9.3%
Pulmonary vasculitis	133	9.2%
Vasculitisinflammation of blood vessels	132	9.1%
Eosinophilic granulomatosis with polyangiitis	130	9%
Respiratory symptom	130	9%
Pain in extremitypain in an arm or leg	125	8.6%
Nauseafeeling sick	121	8.4%
Forced expiratory volume decreased	105	7.3%
No adverse eventno adverse event was reported	102	7.1%
Total lung capacity abnormal	102	7.1%
Productive cougha cough with phlegm	98	6.8%
Pulmonary embolisma blood clot in the lung	97	6.7%
Vomitingbeing sick	97	6.7%
Arteriosclerosis coronary artery	95	6.6%
Normochromic normocytic anaemia	95	6.6%
Conjunctivitis allergic	94	6.5%
Hypoxialow oxygen	94	6.5%
Nodule	94	6.5%
Arteriosclerosis	93	6.4%
Dust allergy	93	6.4%
Mite allergy	93	6.4%
Thrombosis	93	6.4%
Mycotic allergy	92	6.4%
Spirometry abnormal	90	6.2%
Antineutrophil cytoplasmic antibody positive	86	5.9%
Drug ineffectivethe medicine did not work as expected	74	5.1%
Pancreatitisinflammation of the pancreas	58	4%
Sleep disordera sleep problem	57	3.9%
Diarrhoealoose or frequent stools	55	3.8%
Recalled product administered	54	3.7%
Diabetes mellitus inadequate controldiabetes not well controlled	49	3.4%
Acute kidney injurysudden loss of kidney function	48	3.3%
Capillaritis	47	3.3%

Download all 181 terms of Liraglutide (CSV)

The counts add to more than 1,446 reports, because one report can record more than one term. FDA says:

No individual drug is connected to any individual reaction. When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The CSV file has the same rows and the same limits. Its last row is a note that says so.

MedDRA term

The person who codes a report selects the preferred term that agrees best with the description of the reporter. The words under a term are the plain meaning that this site gives.

Not the label

The FDA-approved label of a product lists its adverse reactions. See the official pages at the end of this page.

Same ingredient, other names

Reporters write a brand name or a generic name. Each name has its own page and its own count.

Names of Liraglutide with a page, in the order generic names, brand names, names as reported
Name	Name type	Reports
Liraglutide (this page)	Generic name	1,446
Saxenda	Brand name	6,598
Victoza	Brand name	28,899

Sum of the separately reported names: 36,943. A report that names two of these names is in the sum two times. The sum is not the number of reports for the ingredient.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Outcomes by year

The table gives the outcomes that the reporters gave, in the terms of FDA.

Outcomes in the reports that name Liraglutide, by the year of the openFDA file that holds the report

The table continues to the right.

Year of the openFDA file	Reports	Serious	Death	Life-threatening	Hospitalization (initial or prolonged)	Disability or Permanent Damage	Congenital Anomaly/Birth Defect	Other Serious (Important Medical Events)	Not serious
2010	8	7	1	2	5	0	0	4	1
2011	11	11	1	2	6	1	0	2	0
2012	11	9	1	0	4	0	0	7	2
2013	17	13	0	1	7	0	0	7	4
2014	26	23	0	2	19	0	0	5	3
2015	16	15	1	3	8	0	0	8	1
2016	57	51	0	8	20	1	2	32	6
2017	48	44	3	12	27	2	0	20	4
2018	56	47	1	8	21	2	0	28	9
2019	122	103	4	30	63	3	0	58	19
2020	74	68	16	9	33	2	0	34	6
2021	71	71	1	4	32	0	2	52	0
2022	79	72	11	3	36	0	0	37	7
2023	103	99	11	22	54	1	0	76	4
2024	117	112	20	60	57	0	0	92	5
2025	270	141	30	58	75	6	1	122	129
2026	360	71	18	24	41	4	1	64	289

An outcome in a report is not proof that the drug was the cause. The reporter gives the outcome, and FDA does not verify it. FDA says:

The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The six headings with the names of FDA are the outcome terms of FDA. A report can have more than one outcome. The columns Serious and Not serious are the two values of the openFDA field serious. For the value serious, openFDA gives this description:

The adverse event resulted in death, a life threatening condition, hospitalization, disability, congenital anomaly, or other serious condition
Source: openFDA, Drug adverse event fields (YAML reference). The site read the page on 2 Oct 2026.

The year is the year of the openFDA file that holds the latest version of the report. It is not always the year in which FDA first received the report. The chart of the next section uses the year of first receipt. The latest year is not complete.

Reports by year and month

Reports that name Liraglutide, by the year in which FDA received them

The column of 2026 has an outline, because the year is not complete. It has the reports that FDA received through June 2026 only.

Show the figures of the chart as a table

Reports that name Liraglutide, by the year in which FDA received them
Year	Reports
2010	8
2011	11
2012	12
2013	21
2014	24
2015	18
2016	57
2017	60
2018	60
2019	122
2020	70
2021	83
2022	80
2023	111
2024	135
2025	236
2026	338

Reports that name Liraglutide, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Why a count moves

A count moves for many reasons. The guide gives FDA's words about them.

Patients and reporters

Age of the patient in the reports that name Liraglutide
Age	Reports	Share
Under 2	0	0%
2 to 11	0	0%
12 to 17	8	0.6%
18 to 44	191	13.2%
45 to 64	384	26.6%
65 to 74	334	23.1%
75 and over	82	5.7%
Age not given	447	30.9%

Sex of the patient in the reports that name Liraglutide
Sex	Reports	Share
Female	648	44.8%
Male	574	39.7%
Unknown or not given	224	15.5%

Type of reporter in the reports that name Liraglutide
Reporter	Reports	Share
Physician	250	17.3%
Pharmacist	172	11.9%
Other health professional	400	27.7%
Lawyer	1	0.1%
Consumer or non-health professional	610	42.2%
Not given	13	0.9%

Age and sex are as the report gives them. The reporter is the primary source in the report. 52.2% of the reports give the United States as the country.

Reason for use

Reason for use (indication) that the reports of Liraglutide record
Indication as recorded (MedDRA)	Reports	Share
Type 2 diabetes mellitus	279	19.3%
Diabetes mellitus	225	15.6%
Weight control	74	5.1%
Obesity	28	1.9%
Weight decreased	26	1.8%
Diarrhoea	8	0.6%

The reporter fills in the indication, and the field is often empty. Each share is of all 1,446 reports.

Drugs in the same reports

Other drugs that the reports of Liraglutide name, in any role, in order of name
Drug	Reports that name the two
Albuterol	149
Budesonide	153
Furosemide	155
Insulin glargine	193
Levofloxacin	144
Magnesium oxide	142
Metformin	394
Nucala	152
Pantoprazole	166
Prednisone	168

The table has the 10 drug names that these reports name most. Two names in one report says only that the report recorded the two. It says nothing about the part of a product in the event.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pages near this one

Saxenda same ingredient
Victoza same ingredient
Insulin degludec and liraglutide same class
Mounjaro same class
Foundayo same class
Ozempic same class
Exenatide same class
Rybelsus same class
Liptruzet next in the A to Z list
Liraglutide Flexpen next in the A to Z list
Liposomal Doxorubicin next in the A to Z list
Lisdexamfetamine next in the A to Z list

These links are for navigation. No count selected them. The class page lists each drug of the class.

Official pages

DailyMed labels for LiraglutideThe labels (prescribing information) that have this name, at the National Library of Medicine.
MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Liraglutide: adverse event reports that FDA received. https://reportedreactions.com/drug/liraglutide/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 1 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 1 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Oct 2026. A class is the pharmacologic class (EPC) of the FDA label.

A report is in the count when it names Liraglutide as a suspect or interacting product. The 1,519 reports that name it only as a concomitant medicine are not in the count. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

Do these reports show that Liraglutide was responsible for the reactions?

No. FDA says:

For any given report, there is no certainty that a suspected drug caused the event.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

A reaction can relate to the condition that the drug treats, to other medicines, or to something else.

Is this the list of reactions on the label of Liraglutide?

No. It is a count of what people reported to FDA: 1,446 reports from February 2010 to June 2026. The FDA-approved label of a product lists its adverse reactions. The official pages at the end of this page link to the labels.

Who sent these reports?

Consumer or non-health professional (42.2%), other health professional (27.7%) and physician (17.3%). These are the types of reporter for the reports that name this drug.

If a manufacturer receives an adverse event report, it is normally required to send the report to FDA.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

How does a person report an adverse event?

FDA runs MedWatch, a program that takes voluntary reports from health professionals, patients and consumers. The guide on how to report has the links.

To the top of the page